Portola Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Over-Allotment Option Exercise
5/30/2013 11:05:09 AM
More...
|
Portola Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
5/23/2013 11:30:19 AM
More...
|
Portola Pharmaceuticals, Inc. Announces Oral Presentation of Data on PRT4445, Factor Xa Inhibitor Antidote, at ATVB Scientific Sessions
4/30/2013 11:20:52 AM
More...
|
Portola Pharmaceuticals, Inc. Files for $115 Million IPO
4/15/2013 7:35:10 AM
More...
|
Aciex Therapeutics Enters Into Collaborative Research Agreement With Portola Pharmaceuticals, Inc. to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
2/27/2013 11:15:30 AM
More...
|
Bayer AG (BAY.F), Johnson & Johnson (JNJ) Sign Partner Deal With Portola Pharmaceuticals, Inc. for Xarelto Antidote
2/5/2013 7:16:47 AM
More...
|
Portola Pharmaceuticals, Inc. Initiates Phase 2 Study of PRT4445, Universal Antidote for Factor Xa Inhibitor Anticoagulants
12/10/2012 9:26:14 AM
More...
|
Portola Pharmaceuticals, Inc. Announces Data Presentations From Thrombosis and Syk/JAK Franchises at American Society of Hematology Annual Meeting
12/6/2012 9:41:52 AM
More...
|
Pfizer Inc. (PFE), Bristol-Myers Squibb Company (BMY) to Fund Study of Portola Pharmaceuticals, Inc.'s Blood-Thinner Antidote
11/2/2012 6:31:32 AM
More...
|
Portola Pharmaceuticals, Inc. Announces Upcoming Oral Presentation of Data on PRT4445, a First-in-Class Universal Factor Xa Inhibitor Antidote, at European Society of Cardiology 2012 Congress
8/24/2012 8:27:19 AM
More...
|
|